Catalogo dei prodotti della ricerca

FAGGIANO, ANTONGIULIO
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
NA - Nord America 6.354
EU - Europa 1.647
AS - Asia 701
SA - Sud America 46
AF - Africa 24
Continente sconosciuto - Info sul continente non disponibili 3
OC - Oceania 2
Totale 8.777
Salva come PNG Salva come JPEG
Nazione #
US - Stati Uniti d'America 6.232
IT - Italia 840
IN - India 341
SE - Svezia 265
CN - Cina 164
SG - Singapore 132
CA - Canada 115
IE - Irlanda 95
GB - Regno Unito 71
DE - Germania 61
BG - Bulgaria 60
RO - Romania 51
FI - Finlandia 43
UA - Ucraina 41
AR - Argentina 26
FR - Francia 25
BE - Belgio 21
CH - Svizzera 19
NL - Olanda 17
PH - Filippine 13
TG - Togo 12
VN - Vietnam 10
BR - Brasile 9
PL - Polonia 8
RU - Federazione Russa 8
HK - Hong Kong 7
MX - Messico 7
CL - Cile 6
ES - Italia 6
ID - Indonesia 6
ZA - Sudafrica 6
IR - Iran 5
JO - Giordania 5
TR - Turchia 5
TW - Taiwan 4
CO - Colombia 3
CZ - Repubblica Ceca 3
EE - Estonia 3
PK - Pakistan 3
PT - Portogallo 3
AU - Australia 2
EG - Egitto 2
EU - Europa 2
KR - Corea 2
PE - Perù 2
RS - Serbia 2
UG - Uganda 2
A2 - ???statistics.table.value.countryCode.A2??? 1
AF - Afghanistan, Repubblica islamica di 1
AL - Albania 1
BN - Brunei Darussalam 1
DK - Danimarca 1
DZ - Algeria 1
HR - Croazia 1
MY - Malesia 1
SA - Arabia Saudita 1
SC - Seychelles 1
SI - Slovenia 1
SK - Slovacchia (Repubblica Slovacca) 1
Totale 8.777
Salva come PNG Salva come JPEG
Città #
Fairfield 1.209
Ashburn 517
Woodbridge 505
Seattle 470
Houston 428
Wilmington 404
Cambridge 393
Chandler 329
San Paolo di Civitate 261
Rome 251
Princeton 223
Ann Arbor 149
Lawrence 143
Millbury 142
San Diego 96
Beijing 92
New York 84
Dublin 77
Ottawa 75
Boston 73
Sofia 60
Plano 58
Andover 49
Milan 42
Phoenix 38
Singapore 35
Helsinki 33
Toronto 33
Norwalk 28
Dearborn 27
Pune 27
Federal 26
Bremen 23
Southend 23
Brussels 18
London 14
Bologna 12
Lomé 12
Florence 11
Paris 11
Zurich 11
Des Moines 10
Falls Church 10
Hanoi 10
Boardman 9
Groningen 9
Naples 9
Bühl 8
Hefei 8
Romainville 8
San Mateo 8
Buffalo 7
Cappelle sul Tavo 7
Los Angeles 7
Nanjing 7
Butuan 6
Guangzhou 6
Pavia 6
Redwood City 6
Trumbull 6
Amman 5
Edinburgh 5
Hangzhou 5
Hyderabad 5
Laurel 5
Nanchang 5
Redmond 5
Wuhan 5
Frankfurt am Main 4
Istanbul 4
Livorno 4
Mexico City 4
Moscow 4
Muizenberg 4
Turin 4
Acireale 3
Amsterdam 3
Bari 3
Bern 3
Bogotá 3
Catania 3
Cebu City 3
Chiswick 3
Fremont 3
Grafing 3
Gragnano 3
Hounslow 3
Islamabad 3
Jinan 3
Kaohsiung City 3
Kunming 3
Landshut 3
Lappeenranta 3
Leeds 3
Meda 3
Mugnano di Napoli 3
Mumbai 3
Palu 3
Pescara 3
Pontedera 3
Totale 6.802
Salva come PNG Salva come JPEG
Nome #
Angiogenic factors as prognostic markers in neuroendocrine neoplasms 156
Application of molecular biology of differentiated thyroid cancer for clinical prognostication 98
Combined biological therapy with lanreotide autogel and cabergoline in the treatment of MEN-1-related insulinomas 90
Italian Society of Endocrinology Consensus Statement: Definition, evaluation and management of patients with mild primary hyperparathyroidism 79
Predictive value of pentagastrin test for preoperative differential diagnosis between C-cell hyperplasia and medullary thyroid carcinoma in patients with moderately elevated basal calcitonin levels 78
A decrease of calcitonin serum concentrations less than 50 percent 30 minutes after thyroid surgery suggests incomplete C-cell tumor tissue removal 77
Real-world study of everolimus in advanced progressive neuroendocrine tumors. 75
Accuracy of Fine Needle Cytology in Histological Prediction of Papillary Thyroid Carcinoma Variants: a Prospective Study 75
Transarterial embolization (TAE) is equally effective and slightly safer than transarterial chemoembolization (TACE) to manage liver metastases in neuroendocrine tumors 74
Clinical and prognostic implications of the genetic diagnosis of hereditary NET syndromes in asymptomatic patients 72
Limitations of Chromogranin A in clinical practice 71
Assessment and clinical implications of RANK/RANKL/OPG pathway as markers of bone tumor progression in patients with NET harboring bone metastases 71
Clinical presentation and management of patients with primary hyperparathyroidism in Italy 71
Animal models of medullary thyroid cancer: state of the art and view to the future 71
Thyroid nodules and related symptoms are stably controlled two years after radiofrequency thermal ablation 71
Hepatic arterial embolization in patients with neuroendocrine tumors 71
Head and neck paragangliomas: genetic spectrum and clinical variability in 79 consecutive patients 71
Diagnosis and Differential Diagnosis of Medullary Thyroid Cancer 70
Efficacy and safety of radiofrequency thermal ablation in the treatment of thyroid nodules with pressure symptoms in elderly patients 70
Effect of treatment with depot somatostatin analogue octreotide on primary hyperparathyroidism (PHP) in multiple endocrine neoplasia type 1 (MEN1) patients 69
Hereditary neuroendocrine tumor syndromes 69
The antiproliferative effect of pasireotide LAR alone and in combination with everolimus in patients with medullary thyroid cancer: a single-center, open-label, phase II, proof-of-concept study 69
Selenium supplementation in the management of thyroid autoimmunity during pregnancy: results of the "SERENA study", a randomized, double-blind, placebo-controlled trial 69
A Novel MAX Gene Mutation Variant in a Patient With Multiple and “Composite” Neuroendocrine–Neuroblastic Tumors 69
Cinacalcet hydrochloride in combination with alendronate normalizes hypercalcemia and improves bone mineral density in patients with primary hyperparathyroidism 68
Somatostatin receptor type 2A immunohistochemistry in neuroendocrine tumors: a proposal of scoring system correlated with somatostatin receptor scintigraphy 68
Sorafenib in advanced iodine-refractory differentiated thyroid cancer: efficacy, safety and exploratory analysis of role of serum thyroglobulin and FDG-PET 68
Rare diseases in clinical endocrinology: a taxonomic classification system 67
Metformin Use Is Associated With Longer Progression-Free Survival of Patients With Diabetes and Pancreatic Neuroendocrine Tumors Receiving Everolimus and/or Somatostatin Analogues 66
Advances in the Management of Medullary Thyroid Carcinoma. Focus on Peptide Receptor Radionuclide Therapy 65
Thyroid nodules treated with percutaneous radiofrequency thermal ablation: a comparative study 64
Functional characterization of human thyroid tissue with immunohistochemistry 64
Impact of nutritional status on gastroenteropancreatic neuroendocrine tumors (GEP-NET) aggressiveness 64
Unintentional recurrent laryngeal nerve injuries following thyroidectomy. Is it the surgeon who pays the bill? 64
Second-line sunitinib as a feasible approach for iodine-refractory differentiated thyroid cancer after the failure of first-line sorafenib 63
Predictors of malignancy in high-risk indeterminate (TIR3B) cytopathology thyroid nodules 63
CXCR4/CXCL12/CXCR7 axis is functional in neuroendocrine tumors and signals on mTOR 62
Impact of long-acting octreotide in patients with early-stage MEN1-related duodeno-pancreatic neuroendocrine tumours 62
Heterogeneity of duodenal neuroendocrine tumors: an Italian multi-center experience 61
Sunitinib in patients with pre-treated pancreatic neuroendocrine tumors: a real-world study 61
Preliminary data of VEGF-A and VEGFR-2 polymorphisms as predictive factors of radiological response and clinical outcome in iodine-refractory differentiated thyroid cancer treated with sorafenib 61
The safety of available treatments options for neuroendocrine tumors 60
Open issues on G3 neuroendocrine neoplasms: back to the future 60
Multiple endocrine neoplasia syndrome type 1: institution, management, and data analysis of a nationwide multicenter patient database 60
Targeted therapy with kinase inhibitors in aggressive endocrine tumors 59
Epigenetics in medullary thyroid cancer: from pathogenesis to targeted therapy 59
The evolving field of kinase inhibitors in thyroid cancer 59
PRRT. identikit of the perfect patient 59
Secretive and proliferative tumor profile helps to select the best imaging technique to identify postoperative persistent or relapsing medullary thyroid cancer 58
Diabetes and pancreatic neuroendocrine tumours: which interplays, if any? 58
Natural history of localized and locally advanced lung atypical carcinoid after complete resection: a joined french-italian multicentric retrospective study 58
Genetic-clinical profile of subjects with apparently sporadic extra-adrenal paragangliomas 57
Prognostic factors in ectopic Cushing's syndrome due to neuroendocrine tumors: a multicenter study 57
Quality of life in patients with neuroendocrine neoplasms. The role of severity, clinical heterogeneity and resilience 57
Cinacalcet in the management of primary hyperparathyroidism: post marketing experience of an Italian multicentre group 56
Risk factors of type 1 gastric neuroendocrine neoplasia in patients with chronic atrophic gastritis. A retrospective, multicentre study 56
Efficacy and safety of everolimus in extrapancreatic neuroendocrine tumor: a comprehensive review of literature 56
Emerging multitarget tyrosine kinase inhibitors in the treatment of neuroendocrine neoplasms 56
Clinical management of patients with gastric neuroendocrine neoplasms associated with chronic atrophic gastritis: a retrospective, multicentre study 56
Multimodal imaging with 18F-FDG-PET/CT and 111In-Octreotide SPECT in patients with metastatic medullary thyroid carcinoma 55
Pituitary function and morphology in Fabry disease 55
Role of (68)Ga-DOTATATE PET/CT in patients with multiple endocrine neoplasia type 1 (MEN1) 55
US-guided percutaneous radiofrequency thermal ablation for the treatment of solid benign hyperfunctioning or compressive thyroid nodules 55
GLP-1: benefits beyond pancreas 55
Multiple endocrine neoplasia type 1: analysis of germline MEN1 mutations in the Italian multicenter MEN1 patient database 55
Complete disappearance of liver metastases in a patient with iodine-refractory differentiated thyroid cancer subjected to sorafenib re-challenge 55
Everolimus as first line therapy for pancreatic neuroendocrine tumours: current knowledge and future perspectives 54
Somatostatin analogues according to Ki67 index in neuroendocrine tumours: an observational retrospective-prospective analysis from real life 54
Biliary Stone Disease in Patients with Neuroendocrine Tumors Treated with Somatostatin Analogs. A Multicenter Study 54
A classification prognostic score to predict OS in stage IV well-differentiated neuroendocrine tumors 54
Capecitabine and Temozolomide (CAPTEM) in advanced neuroendocrine neoplasms (NENs): a systematic review and pooled analysis 53
Contrast enhanced multi-detector CT and MR findings of a well-differentiated pancreatic vipoma 53
Therapeutic sequences in patients with grade 1−2 neuroendocrine tumors (NET): an observational multicenter study from the ELIOS group 53
Chromogranin a as circulating marker for diagnosis and management of neuroendocrine neoplasms: More flaws than fame 52
Cinacalcet therapy in patients affected by primary hyperparathyroidism associated to Multiple Endocrine Neoplasia Syndrome type 1 (MEN1) 52
Potential role of cinacalcet hydrochloride in sporadic primary hyperparathyroidism without surgery indication 51
Rapidly progressing high o,p'DDD doses shorten the time required to reach the therapeutic threshold with an acceptable tolerance: preliminary results 51
Screening of pancreaticoduodenal endocrine tumours in patients with MEN 1: multidetector-row computed tomography vs. endoscopic ultrasound 51
Bone metastases in neuroendocrine neoplasms: from pathogenesis to clinical management 51
Circulating tumor cells and miRNAs as prognostic markers in neuroendocrine neoplasms 50
Natural History and Management of Familial Paraganglioma Syndrome Type 1: Long-Term Data from a Large Family 50
Bone metabolism, bone mass and structural integrity profile in professional male football players 50
Epidemiology of pancreatic neuroendocrine neoplasms. a gender perspective 50
Risk factors for gastroenteropancreatic neuroendocrine neoplasms (GEP-NENs): a three-centric case–control study 50
Epidemiology of gastroenteropancreatic neuroendocrine tumours. 49
Pasireotide in the treatment of neuroendocrine tumors: a review of the literature 48
The medical treatment of Cushing's disease: effectiveness of chronic treatment with the dopamine agonist cabergoline in patients unsuccessfully treated by surgery 48
Spinal deformity index in patients with type 2 diabetes 47
Thyroid profile during the alternative Sunitinib dosing 2/1 schedule in metastatic renal cell carcinoma 47
Emerging therapies in pheochromocytoma and paraganglioma. immune checkpoint inhibitors in the starting blocks 47
Diagnosis of Flier's syndrome in a patient with nondiabetic hypoglycemia. a case report and critical appraisal of the literature 47
Epidemiology of non-gastroenteropancreatic (neuro)endocrine tumours 46
Pathology reporting in neuroendocrine neoplasms of the digestive system: everything you always wanted to know but were too afraid to ask 46
Case Report. Unmasking Hypercalcemia in Patients With Neuroendocrine Neoplasms. Experience From Six Italian Referral Centers 45
Commentary: case report: abdominal lymph node metastases of parathyroid carcinoma: diagnostic workup, molecular diagnosis, and clinical management 45
Immune Checkpoint Blockade in Lung Carcinoids with Aggressive Behaviour. One More Arrow in Our Quiver? 45
Pancreatic neuroendocrine neoplasms. Does sex matter? 44
Predictive factors of response to mTOR inhibitors in neuroendocrine tumours 43
Role of contrast-enhanced ultrasound to define prognosis and predict response to biotherapy in pancreatic neuroendocrine tumors 43
BRAF V600E assessment by pyrosequencing in fine needle aspirates of thyroid nodules with concurrent Hashimoto's thyroiditis is a reliable assay 43
Totale 6.039
Salva come PNG Salva come JPEG
Categoria #
all - tutte 34.425
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 34.425
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2018/2019302 0 0 0 0 0 0 0 0 0 0 138 164
2019/20202.630 169 158 74 157 283 248 321 322 319 271 103 205
2020/20211.061 121 176 73 33 71 72 51 76 146 93 100 49
2021/20222.108 39 84 191 92 240 45 66 227 204 81 485 354
2022/20232.205 405 486 80 186 163 142 31 119 318 52 152 71
2023/20241.317 96 209 75 144 155 287 68 81 24 172 6 0
Totale 9.861